Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
Candel Therapeutics (CADL) shares dropped 35% premarket after delaying its BLA submission for aglatimagene besadenovec to mid-2027. The company cited assay refinements and FDA discussions. Q3 net loss widened to $21.9M. Stifel cut its price target to $19. Candel has $203.1M in cash, expected to last into Q2 2028.
How this was made
The 30-second read
Why it matters
The BLA delay signals higher regulatory risk and pushes back revenue expectations, which drove a 35% pre‑market decline.
Market read
The news is a primary disclosure of a regulatory timeline shift and Q3 loss widening, creating immediate trading relevance for CADL.
What to watch
Cash runway remains strong through 2028, potentially supporting future milestones.
Background
Candel Therapeutics (NASDAQ:CADL) is a clinical‑stage company developing gene‑therapy candidates for prostate cancer and other indications.
Ticker impact
Candel Therapeutics announced a six‑month delay to its BLA filing for aglatimagene besadenovec, pushing the target to mid‑2027 and reporting a widened Q3 net loss.
downward pressure as investors price in the delayed approval timeline and higher regulatory risk
Premarket sell‑off of 35% reflects immediate reaction; the delay is material for a clinical‑stage biotech.
Market effects
May weigh on other prostate‑cancer biotech peers as regulatory timelines tighten.
Limited to US‑listed biotech sector.
Low; impact confined to niche oncology investors.
Counterpoint
If the CMC work proceeds smoothly, the delay could be a temporary setback, and the stock may be oversold.
Key entities
- companyCandel Therapeutics Inc
Clinical‑stage biopharma developing aglatimagene besadenovec.
- analystStifel
Lowered price target to $19 from $22 following the delay.
